OBI Pharma, Inc. (OBI), a global clinical-stage oncology company specializing in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174.TWO), and TegMine Therapeutics, Inc. (TegMine), a US biopharmaceutical company developing first-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related master services agreement..

浩鼎生技股份有限公司（OBI）是一家全球临床阶段的肿瘤学公司，专注于开发新型癌症疗法，如抗体药物偶联物（ADCs）（4174.TWO），与美国生物制药公司TegMine Therapeutics, Inc.（TegMine）达成了与ADC相关的主服务协议，后者致力于开发针对癌症聚糖和糖蛋白的首创抗体。

Under the agreement, OBI grants TegMine the rights to use OBI's GlycOBI® ADC  technologies, based on EndoSymeOBI® and  HYPrOBI® , to identify ADC treatment candidates for potential clinical development. Should one or more ADC product candidates emerge, OBI and TegMine will enter into a formal license agreement..

根据协议，OBI授予TegMine使用OBI的GlycOBI® ADC技术的权利，该技术基于EndoSymeOBI®和HYPrOBI®，用于识别潜在临床开发的ADC治疗候选药物。如果出现一个或多个ADC产品候选药物，OBI和TegMine将签订正式的许可协议。

'This strategic collaboration leverages the synergistic strengths of both companies,' said Dr. Heidi Wang, Chief Executive Officer of OBI Pharma. 'We aim to advance OBI's compelling ADC products and leverage innovative ADC technologies such as GlycOBI® for a strategic partnership. We look forward to working closely with TegMine to generate new ADC candidates to treat patients with high unmet medical needs.'.

“这一战略合作充分利用了两家公司的协同优势，”浩鼎生技首席执行官王海蒂博士表示，“我们旨在推进浩鼎令人瞩目的ADC产品，并利用诸如GlycOBI®这样的创新ADC技术进行战略合作。我们期待与TegMine密切合作，开发新的ADC候选药物，以治疗具有高度未满足医疗需求的患者。”

'This collaboration represents the exciting convergence of two innovative platforms,' ​​said Dr. Jeff Bernstein, Chief Executive Officer of TegMine Therapeutics. 'OBI's ADC technology perfectly complements our efforts to target cancer-specific glycans. Together, we have the opportunity to develop ADCs with unprecedented tumor specificity and therapeutic efficacy.'.

“这次合作代表了两个创新平台的令人兴奋的融合，”TegMine Therapeutics首席执行官Jeff Bernstein博士表示。“OBI的ADC技术完美地补充了我们针对癌症特异性聚糖的努力。共同合作，我们有机会开发出具有前所未有的肿瘤特异性和治疗效果的ADC。”

About GlycOBI ®

关于GlycOBI®

OBI has developed a unique glycan-based ADC technology (GlycOBI ® ) available in a plug-and-play format and compatible with all antibodies, linkers, and drugs at various drug-antibody ratios (DARs). Using OBI's proprietary enzyme technology (EndoSymeOBI ® ) and linker technology (HYPrOBI TM ), GlycOBI ® produces site-specific, homogeneous ADCs in an efficient and scalable process under GMP conditions.

OBI开发了一种独特的基于聚糖的ADC技术（GlycOBI®），采用即插即用格式，兼容所有抗体、连接子和药物，并适用于不同的药物抗体比（DARs）。利用OBI专有的酶技术（EndoSymeOBI®）和连接子技术（HYPrOBI™），GlycOBI®能够在GMP条件下通过高效且可扩展的工艺生产位点特异性、均质的ADC。

GlycOBI ® 's conjugation process prevents disruption of the antibody structure and ensures that the ADC exhibits similar biophysical properties to the native antibody. Furthermore, OBI's linker technology has improved the payload conjugation efficiency and reduced aggregation tendency, significantly improving the manufacturing of ADC products.

GlycOBI ® 的结合过程防止了抗体结构的破坏，并确保ADC表现出与天然抗体相似的生物物理特性。此外，OBI的连接子技术提高了有效载荷的结合效率并降低了聚集倾向，大幅改善了ADC产品的生产。

GlycOBI ® has overcome the limitations of conventional ADCs and demonstrated superior antitumor activity and stability in various animal studies..

GlycOBI ® 已克服了传统ADC的局限性，并在各种动物研究中展现出卓越的抗肿瘤活性和稳定性。

About OBI Pharma

关于浩鼎生技

OBI is a global clinical-stage oncology company headquartered in Taiwan, founded in 2002. Together with its subsidiary OBI Pharma USA, Inc., it is committed to developing novel cancer medicines for patients with high unmet medical needs.

OBI是一家总部位于台湾的全球临床阶段肿瘤学公司，成立于2002年。与其子公司OBI Pharma USA, Inc.一起，致力于为具有高度未满足医疗需求的患者开发新型癌症药物。

OBI is primarily focused on developing novel ADCs, including the first-generation cysteine-based TROP-2 ADC, OBI-992. Using its proprietary ADC technology GlycOBI® , based on EndoSymeOBI® and HYPrOBI™, OBI has developed a second generation of its innovative ADC pipeline, including monospecific ADCs such as OBI-902 (TROP-2), OBI-904 (Nectin-4), and trastuzumab ADC (HER2), as well as bispecific and dual-payload variants.

OBI主要专注于开发新型ADC，包括第一代基于半胱氨酸的TROP-2 ADC（OBI-992）。利用其专有的ADC技术GlycOBI®（基于EndoSymeOBI®和HYPrOBI™），OBI已开发出第二代创新ADC管线，包括单特异性ADC，如OBI-902（TROP-2）、OBI-904（Nectin-4）和曲妥珠单抗ADC（HER2），以及双特异性和双载荷变体。

To expand the applicability of the HYPrOBI™ linker technology, OBI has also developed a next-generation ThiOBI® platform enabling cysteine-based conjugation. OBI also has the first small molecule prodrug, OBI-3424, in its pipeline, targeting AKR1C3. This drug delivers a potent DNA-alkylating agent against tumors in the presence of the enzyme aldo-keto reductase 1C3 (AKR1C3), which is commonly expressed in tumors.

为了扩展HYPrOBI™连接子技术的适用性，OBI还开发了下一代ThiOBI®平台，支持基于半胱氨酸的偶联。OBI还拥有其管线中的首个小分子前药OBI-3424，靶向AKR1C3。该药物在醛酮还原酶1C3（AKR1C3）存在的情况下，释放出强效的DNA烷基化剂对抗肿瘤，而AKR1C3在肿瘤中普遍表达。

For more information, please visit  www.obipharma.com ..

欲了解更多信息，请访问 www.obipharma.com。

GlycOBI ® , EndoSymeOBI ® , and ThiOBI ® are registered trademarks of OBI. HYPrOBI™ is a registered trademark.

GlycOBI®、EndoSymeOBI® 和 ThiOBI® 是 OBI 的注册商标。HYPrOBI™ 是注册商标。

About TegMine Therapeutics

关于TegMine治疗学

TegMine Therapeutics is a privately held biotechnology company based in San Francisco, California, USA, specializing in the development of antibody-based therapies targeting cancer-related glycans and glycoproteins. Founded in 2017, TegMine is pioneering a highly selective approach to cancer treatment, focusing on tumor-specific carbohydrate antigens that are virtually absent from healthy tissue.

TegMine Therapeutics是一家总部位于美国加利福尼亚州旧金山的私营生物技术公司，专注于开发针对癌症相关聚糖和糖蛋白的抗体疗法。公司成立于2017年，正致力于开创一种高度选择性的癌症治疗方法，专注于几乎不存在于健康组织中的肿瘤特异性碳水化合物抗原。

These novel targets are being developed into a diverse pipeline of antibody-drug conjugates (ADCs), bispecific antibodies, and cell therapies..

这些新靶点正被开发成一个多样化的抗体药物偶联物（ADC）、双特异性抗体和细胞疗法的管线。

TegMine's proprietary TegMiner™ platform enables the discovery and development of therapeutic antibodies against previously inaccessible glycan epitopes, opening entirely new doors in oncology for patients with high medical needs.

TegMine的专有TegMiner™平台能够发现和开发针对以前无法触及的聚糖表位的治疗性抗体，为高医疗需求的患者在肿瘤学领域开启了全新的大门。

For more information, please visit  www.tegminetx.com

欲了解更多信息，请访问 www.tegminetx.com

Forward-looking statements

前瞻性声明

Statements contained in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding future clinical trials, results, and the timing of such trials and results.

本新闻稿中包含的非历史事实描述的陈述，是根据1995年《私人证券诉讼改革法案》所定义的前瞻性陈述。这些前瞻性陈述包括但不限于关于未来临床试验、结果以及此类试验和结果时间的陈述。

Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Commission..

此类风险因素会在OBI Pharma的报告和简报中不时被识别和讨论，包括OBI Pharma向台湾证券期货委员会提交的文件。

Company Contacts:

公司联系人：

Kevin Poulos, Chief Business Officer

凯文·普洛斯，首席商务官

OBI Pharma USA, Inc.

欧比制药美国公司

+1 (619) 537-7698, ext. 102

+1 (619) 537-7698，分机102

kpoulos@obipharma.com

科波罗斯@奥比制药公司.com

Jeff Bernstein, CEO

杰夫·伯恩斯坦，首席执行官

TegMine Therapeutics, Inc.

TegMine治疗公司

operations@tegminetx.com

operations@tegminetx.com

Source: globenewswire.com

来源：globenewswire.com